Oxford University Hospitals NHS Trust, Oxfordshire Primary Care Trust, Oxfordshire Clinical Commissioning Group and Oxford Health NHS Trust
|
|
- Abel Quinn
- 5 years ago
- Views:
Transcription
1 Oxford University Hospitals NHS Trust, Oxfordshire Primary Care Trust, Oxfordshire Clinical Commissioning Group and Oxford Health NHS Trust Shared Care Protocol and Information for GPs TERIPARATIDE, rhpth (1-34) (FORSTEO ) This shared care guideline provides the necessary information and guidance for the shared care of adult patients requiring teriparatide rhpth (1-34) (FORSTEO ) therapy Summary NICE technology appraisal guidance 161 Alendronate, etidronate, risedronate, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women was published in October 2008 and amended in January 2010 and January Background Teriparatide is a recombinant form of naturally occurring parathyroid hormone. It stimulates new bone formation i.e. is anabolic and also increases resistance to fracture. Indications Teriparatide is licensed for treatment of osteoporosis; in postmenopausal women and in men at increased risk of fracture, associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture Teriparatide is recommended by NICE in TA 161 as a treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are either: 1. unable to take alendronate and either risedronate or etidronate, or have a contraindication to or are intolerant of alendronate and either risedronate or etidronate (defined as persistent upper gastrointestinal disturbance that is sufficiently severe to warrant discontinuation of treatment despite instructions for administration having been followed correctly) or 2. who have a contraindication to or are intolerant of strontium (defined as persistent nausea or diarrhoea either of which warrants discontinuation of treatment) or 3. who have had an unsatisfactory response to treatment with alendronate, risedronate or etidronate (defined as occurring when a woman has another fragility fracture despite adhering to treatment for 1 year and there is evidence of a decline in BMD below her pre-treatment baseline. NICE defines a fragility fracture as one sustained as the result of a force equivalent to the force of a fall from a height equal to, or less than, that of an ordinary chair.) AND either: years or older and have a T score of -4.0SD or below or years or older and have a T score of -3.5SD or below plus more than two fractures or 3. who are aged years and have a T score of -4SD or below plus more than two fractures 1
2 Criteria for consideration of teriparatide therapy (All criteria must be met) The attached Teriparatide Baseline Patient Pro-Forma should be completed and copies forwarded to both the Oxfordshire PCT Medicines Management Team and the Patient s GP. i. Post menopausal female ii. Age 55 years or over iii. A) An unsatisfactory response to bisphosphonate therapy, defined as another fragility fracture despite adhering fully to treatment for one year and when there is also evidence of a decline in BMD below the pretreatment baseline. Or B) Intolerant to oral bisphosphonate therapy, defined as persistent upper gastrointestinal disturbance that is sufficiently severe to warrant discontinuation of treatment and which occurs even though instructions for administration have been correctly followed. Or C) Contraindication or intolerant to strontium, defined as persistent nausea and diarrhoea either of which warrants discontinuation of treatment Or D) Contraindication to or intolerance of denosumab that warrants discontinuation of treatment AND iv. Very high fracture risk, defined as secondary prevention of osteoporotic fragility fractures with: 65 years or older and with a T score of -4.0SD or below or 65 years or older and with a T score of -3.5SD or below plus more than two fractures or years and with a T score of -4SD or below plus more than two fractures For patients over 75 years who have not previously had the BMD measured and who have one or more independent clinical risks for fractures (parental history of hip fracture, alcohol intake of 4 or more units per day, rheumatoid arthritis) or indicators of low BMD, a DXA scan may not be required if the responsible clinician considers it to be clinically inappropriate or unfeasible, providing they also fulfill criterion iii. v. Patient (patient and carer where needed) consent and able to cope with up to 18 months treatment by daily subcutaneous injection. Prescribing Information / Dose The recommended dose of teriparatide is 20 micrograms administered once daily by subcutaneous injection in the thigh or abdomen. The maximum total duration of treatment with teriparatide under the product license should be 24 months The 24-month course of teriparatide (Forsteo ) should not be repeated over a patient's lifetime. In accordance with NICE Oxfordshire patients should not be treated for more than 18 months unless this has been approved by the Medicines Management Team Patients should receive locally recommended supplemental calcium and vitamin D supplements unless clinician is confident that dietary intake is sufficient Other osteoporosis treatments e.g. alendronate, risedronate and strontium ranelate should not be used concomitantly with teriparatide and should be discontinued. Following cessation of teriparatide therapy, patients may be continued on other osteoporosis therapies. Advice should be sought from the Osteoporosis Centre if this is considered. 2
3 Administration Teriparatide is supplied as pre-filled disposable pens, each containing 28 doses. The patient (or their carer) must be trained to use the proper injection technique. A new insulin pen injection needle should be used with the pen for every injection. Storage should be at 2-8 C at all times with the pen returned to the refrigerator immediately after use. Training of patient (patient carer) to self administer Training is provided by the specialist home delivery service Adverse effects The Summary of Product Characteristics states; of patients in the teriparatide trials, 82.8% of the teriparatide patients and 84.5% of the placebo patients reported at least 1 adverse event. The most commonly reported adverse reactions in patients treated with teriparatide are nausea, pain in limb, headache and dizziness. Very common ( 1/10) Limb pain Common ( 1/100 to <1/10), palpitations, anaemia, dizziness, headache, sciatica, syncope, vertigo, dyspnoea, nausea, vomiting, hiatus hernia, GORD, increased sweating, muscle cramps, hypercholesterolaemia, hypotension, Fatigue, Chest pain, Asthenia, Mild and transient injection site events, including pain, swelling, erythema, localised bruising, pruritus and minor bleeding at injection site, depression In patients suffering from transient orthostatic hypotension or dizziness, these patients should refrain from driving or use of machines until symptoms have subsided. Uncommon ( 1/1,000 to <1/100) Tachycardia, emphysema, haemorrhoids, urinary incontinence, polyuria, micturation urgency, nephrolithiasis, myalgia, arthralgia, back cramp/pain, hypercalcaemia greater than 2.76 mmol/l, hyperuricaemia, injection site erythema and reaction, weight increase and cardiac murmur. Rare ( 1/10,000 to <1/1,000) Renal failure/impairment, hypercalcaemia greater than 3.25 mmol/l, possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral) All adverse effects should be reported to the GP and the consultant for advice. Contra-indications/Cautions: Should not be used in patients with severe renal impairment (egfr < 29 ml/min/1.73m²) Use with caution in patients with moderate renal impairment (egfr ml/min/1.73m²) Hypersensitivity to teriparatide or any of its excipients Pre-existing hypercalcaemia Metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget s disease of the bone) Unexplained elevations of alkaline phosphatase Prior radiation therapy to the skeleton Pregnancy and lactation Studies in rabbits have shown reproductive toxicity (please refer to SPC). The potential risk to humans is unknown. Given the indication, teriparatide should not be used during pregnancy or by breast feeding women. Drug interactions Because teriparatide transiently increases serum calcium, it should be used with caution in patients taking digoxin. 3
4 Pre-Treatment Monitoring by Specialist BMD: Pre treatment DXA / Baseline T Score: Needed in order to determine whether patient meets NICE criteria (unless over 75 years as detailed above) Serum Calcium Level: Pre treatment monitoring required Renal Function:: Pre treatment monitoring required (Should not be used in patients with severe renal impairment and in caution in patients with moderate renal impairment) Alkaline phosphatase (Alk Phos): Pre treatment monitoring required (Should not be used in patients with unexplained elevations of alkaline phosphatase) NICE suggests formal assessment of calcium and vitamin D status is not necessary.nice assumes that women who receive treatment have an adequate calcium intake and are vitamin D replete. Unless clinicians are confident that women who receive treatment meet these criteria, calcium and or vitamin D supplementation should be considered In normocalcaemic patients, slight transient elevations of serum calcium have been observed following teriparatide injection. Serum calcium concentrations reach a maximum between 4 and 6 hours and return to baseline by 16 to 24 hours after each dose of teriparatide. Routine calcium monitoring during therapy is not required. If any blood samples are taken from a patient, this should be at least 16 hours after the most recent injection. Patient information leaflet Patients should be supplied with an information leaflet from the manufacturer and- the hospital team. NICE also provides an information leaflet about TA 161. Shared Care Responsibilities Shared care assumes communication between the specialist, GP and patient. The intention to share care should be explained to the patient and accepted by them. Patients should be under regular follow-up which provides an opportunity to discuss drug therapy. a) Aspects of care for which the Hospital Consultant is responsible: At initiation Confirm the patients BMD perform lateral spinal x-rays or MRI scan and check bone biochemistry and PTH. This will also be recorded on the pro-forma (see below) Measurement of BMD using central (hip and or spine) DXA scanning should be used to estimate fracture risk. Exclude contra-indications listed on shared care protocol: This will also be recorded on the pro-forma Ensure the patient understands the nature and complications of drug therapy and their role in reporting adverse effects promptly. Ensure discontinuation of other treatments, especially bisphosphonates Complete patient pro-forma in order to confirm that the patient meets the NICE criteria and that all necessary monitoring and stabilisation has been completed. Send to Oxfordshire Medicines Management Team for prior approval in accordance with the contract and send copy to GP. Register the patient with the specialist home deliver service, sending a copy of the registration from to the Oxfordshire Medicines Management Team and prescribe three months supply of teriparatide on monthly FP10 hospital prescriptions plus calcium and vitamin D, according to status, on a separate FP10 hospital prescription. Contacting GP for shared care In the absence of adverse reactions arrange shared care with the patients GP & PCT at three month review by writing to the GP requesting shared care and outline shared care protocol criteria. Advise GP of the need to continue to prescribe appropriate supplementation unless patient s dietary intake is deemed sufficient. Ensure clinical supervision of the patient is done by follow-up as appropriate: Review the patient between 3 and 18 months, only if required due to their situation changing, adverse drug reactions or compliance issues highlighted by the patient or GP. Provide clear instruction to GP on when therapy needs to be referred back to specialist. Advise the GP when to stop treatment and give advice on any further treatment of osteoporosis. 4
5 Provide written communication directly to GP regarding changes in disease management, drug dose, missed clinic appointments. Be available to give advice and support to GP and patient. At 18 months To follow up patient and assess response to treatment at 18 months by completing a repeat BMD Complete follow up teriparatide patient proforma if desired and send to Oxfordshire Medicines Management Team as an exceptional funding request. Send copy to GP b) Aspects of care for which the GP is responsible: After 3 months of specialist prescribing to prescribe (teriparatide) according to a written protocol. Prescribe calcium and vitamin D supplements if required unless contraindicated. Monitor for adverse effects as detailed above Report any adverse events of teriparatide to the consultant and seek advice if necessary. Stop treatment after 18 months (unless exceptional funding has been agreed) or earlier if advised to do so by the consultant. Advise the Hospital Consultant of any clinical changes where appropriate. c) Aspects of care for which the specialist home delivery service are responsible for: The manufacturers of teriparatide (Forsteo ) operate a specialist home delivery and support service for patients who are prescribed teriparatide injection, provided by Healthcare at Home, in collaboration with Eli Lilly Company Limited: Forsteo Homecare (FHC). On receipt of the patient registration by the specialist home delivery service from the consultant, the specialist home delivery service should confirm funding from the Oxfordshire Medicines Management Team for each individual patient considered to meet the criteria for treatment. The PCT will guarantee funding for all patients that meet the NICE criteria, for up to 18 months treatment. This service provides support for the patient in two main areas: o Delivery of the drug and all items (injection needles etc) to support the use of injections o Training in storage and administration of the drug To contact patient and arrange a convenient time for specialist home deliver service nurse training and teriparatide delivery To provide delivery of the drug and any items to support the use of injections (pen needles and waste disposal facilities monthly for months 1-3 and every 3 months thereafter, ensuring an unbroken cold chain to the patient s home To provide a collection service for clinical and pharmaceutical waste. The specialist home deliver service nurse will train the patient in their own home to administer the drug subcutaneously and provide support until the patient is competent. To monitor compliance for the first 3 months and check for any adverse events. To flag up any issues with hospital clinician. The patient will be able to call the specialist homecare nurse 24 hours a day, or the Forsteo telephone helpline on (Mon-Fri 8am to 6pm) in case of problems or queries. The essential requirements for this service are: 1. All patients will require initial registration with the specialist home care company (Forsteo Homecare (FHC) The consultant will complete the necessary documentation which includes the name and address and telephone number of the patient s GP. A copy of the registration form will be forwarded to the GP and PCT together with a copy of this shared care guideline, after 3 months once the patient has been stabilised. 2. Three hospital FP10 (NC) prescriptions each for one month s supply of teriparatide are sent by post with the registration form to FHC. 5
6 3. The Pharmacist at Healthcare at Home will ensure legal validation and will clinically check the information provided. Once satisfied that the prescription is suitable for dispensing then the process of delivering the drug commences. 4. FHC will contact the patient directly at home and agree a time and date for delivery. A qualified nurse will call at the patient s home within 24 working hours of delivery to commence the training of the patient in the storage and administration of the drug, which will be accompanied by a training package that the patient will have for their use. 5. During the first three months, patients will be requested to send back their pens at the end of the 28 days of use in pre-paid envelopes to FHC. The remaining volume will be measured that will indicate the degree of compliance. This will be communicated back to the clinicians both GP and consultant in the form of a report. 6. Further prescriptions will be prompted by FHC who will contact the GP in good time for a repeat prescription. Pre-paid envelopes are provided by FHC. GP practices are requested to put systems in place to monitor this in order to prevent the potential for over prescribing / supply. Prescriptions will be dispensed and delivered monthly for the first 3 months then every 3 months thereafter d) Aspects of care for which the Patient / (Patients Carer if they are administering) is responsible: To ensure they have a full understanding of the treatment To report any adverse events to the GP and / or consultant To store, prepare and administer the medication properly and safely Attend for regular appointments as requested Contact Details Dr M Kassim Javaid Kerri Rance Nurse Specialist Osteoporosis Healthcare at Home Limited Customer Service Lilly Customer Care Oxford University Hospitals Trust Medicines Information Department This is intended as an outline guide for further information please refer to the Summary of Product Characteristics or above contacts. 6
Crawley CCG LCS Dec 15 Final
Crawley CCG LCS Dec 15 Final Crawley CCG Service Proposal for the inclusion of administration and monitoring of Denosumab 60mg Injection (Prolia )in GP Practices under a Locally Commissioned Service February
More informationPatient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPATIENT GROUP DIRECTION (PGD) FOR THE
PGD 1 PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF DARBEPOETIN ALFA BY RENAL NURSES TO PATIENTS ATTENDING THE RENAL UNIT, MONKLANDS HOSPITAL, FOR HAEMODIALYSIS /HAEMODIAFILTRATION This document
More informationPGD5417. Clinical Performance Director of Nursing Allison Bussey
PGD5417 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses and Midwives employed by South Staffordshire & Shropshire Healthcare Foundation
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2015
Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationWelcome to Pinnacle Chiropractic Spine and Sports Center
Welcome to Pinnacle Chiropractic Spine and Sports Center Name: Social Security Number: : Address: City: State: Zip: _ Telephone Home: Work: Mobile: _ Age: of Birth: Height: Weight: Gender: M / F Employer:
More informationPlease call the Pharmacy Medicines Unit on or for a copy.
Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This
More informationWelcome to Pinnacle Chiropractic Spine and Sports Center
Welcome to Pinnacle Chiropractic Spine and Sports Center Name: Social Security Number: : Address: City: State: Zip: _ Telephone Home: Work: Mobile: _ Age: of Birth: Height: Weight: Gender: M / F Employer:
More informationName Job Title Signed Date
PGD3517 PATIENT GROUP DIRECTION FOR THE SUPPLY OF AZITHROMYCIN TABS/CAPS 250mg or TABS 500mg OR SUSPENSION 600mg/15mL FOR UNCOMPLICATED GENITAL CHLAMYDIA TRACHOMATIS, UNCOMPLICATED NEISSERIA GONORRHOEA
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES
Use for a resident who has potentially unnecessary medications, is prescribed psychotropic medications or has the potential for an adverse outcome to determine whether facility practices are in place to
More informationCroydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement
Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net e-mail: Consultant
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationSHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) CO-CODAMOL 30/500 TABLETS FOR MINOR INJURIES UNITS Trust Ref No 1956-35206 Local Ref (optional) Main points the document treatment of moderate pain
More informationNHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration)
GG&C PGD ref no: 2017/1523 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults
More informationPatient Group Drection (PGD) Number : Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 (Gardasil )
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationAranesp (Darbepoetin) for Renal Anaemia
Aranesp (Darbepoetin) for Renal Anaemia Information for patients, relatives and carers Renal Department York and Scarborough Hospitals Tel: 01904 725370 For more information, please contact: Renal Anaemia
More informationName Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019
PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed
More informationOxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients
Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie
More informationVertebroplasty. Exceptional healthcare, personally delivered
Vertebroplasty Exceptional healthcare, personally delivered Your Doctor has requested that you have a vertebroplasty. We hope the following information will answer some of the questions you may have about
More information1. Guidance notes. Social care (Adults, England) Knowledge set for medication. What are knowledge sets? Why were knowledge sets commissioned?
Social care (Adults, England) Knowledge set for medication 1. Guidance notes What are knowledge sets? Part of the sector skills council Skills for Care and Development Knowledge sets are sets of key learning
More informationNeck & Spine Patient Demographic
Neck & Spine Patient Demographic o New Patient o Return Patient o Update Account #: Physician: Last Name First Name MI: Address City State Zip Home Phone o OK to Leave Msg. Work Phone o OK to Leave Msg.
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationPROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS
PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS Document Details Title Procedure for the administration of Homely Remedies in Community Hospitals Trust Ref No 1896-36344 Local
More informationThe CMS State Operations Manual Overview and Changes
The CMS State Operations Manual Overview and Changes Omnicare, Inc. Page 1 Overview of the CMS State Operations Manual Executive Summary Historical Perspective The Requirements Pharmacy Services Labeling
More informationInitiation of Warfarin for patients not registered with Provider Practice
Initiation of Warfarin for patients not registered with Provider Practice 2017-18 1. Purpose of Agreement This Agreement outlines the service to be provided by the Provider, called Initiation of Warfarin
More informationMartina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist
Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:
More informationPatient s Legal Name: Preferred Name: First Middle Last
Douglas County Dental Clinic Patient Registration Revised August 2016 We REQUIRE A Parent, Guardian, Or Other Legally Responsible Party To Complete & Sign all forms. Please provide a photo ID, Proof of
More informationThe use of Homely Remedies in Care Homes
Good Practice Guidance: The use of Homely Remedies in Care Homes The aim of this guidance is to: Support and advise care homes in the development of a homely remedy policy that adheres to the NICE good
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationSection 6: Referral record headings
Section 6: Referral record headings Referral record standards: the referral headings are primarily intended for recording the clinical information in referral communication between general practitioners
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More information*Your Name *Nursing Facility. radiation therapy. SECTION 2: Acute Change in Condition and Factors that Contributed to the Transfer
Gaining information about resident transfers is an important goal of the OPTIMISTC project. CMS also requires us to report these data. This form is where data relating to long stay transfers are to be
More informationPATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title
Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationGG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation
More informationU: Medication Administration
U: Medication Administration Alberta Licensed Practical Nurses Competency Profile 199 Competency: U-1 Pharmacology and Principles of Administration of Medications U-1-1 U-1-2 U-1-3 U-1-4 Demonstrate knowledge
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP
More informationPolicy :Department of Cardiology
Policy :Department of Cardiology Title: PROTOCOL FOR CARDIAC NURSE SPECIALIST PERFORMING IMPLANTABLE CARDIAC MONITOR PROCEDURE Authors: Simon Adams Accepted by: Acute Care Division Active date: Ratification
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine
More informationORAL ANTI-CANCER THERAPY POLICY
ORAL ANTI-CANCER THERAPY POLICY Document Author Written By: Lead Oncology Pharmacist Authorised Authorised By: Chief Executive Officer Date: vember 2016 Date: 11 th April 2017 Lead Director: Executive
More informationAppendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD)
Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD) PGD for the supply/administration of: Lidocaine 1% and Adrenaline 1:200,000 Master document reference number: This
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE. Patient s first names
Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Cisplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS Version 4 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse
More informationAll Wales Multidisciplinary Medicines Reconciliation Policy
All Wales Multidisciplinary Medicines Reconciliation Policy June 2017 This document has been prepared by the Quality and Patient Safety Delivery Group of the All Wales Chief Pharmacists Group, with support
More informationFacilitate arranging treatment around friends and family and organise social activities
Home Infusion Guide VPRIV (velaglucerase alfa for infusion) Gaucher disease, treatment and home infusion Together with your treating physician, you have decided to start home infusion therapy with VPRIV.
More informationOffice Hours Our office hours are Monday through Friday 7:30 am to 5:30pm. Our office is closed on all major Holidays.
Dear New Patient: We would like to welcome you to our practice. Our goal is to make your experience with us as pleasant as possible. In order to help us meet this goal we have listed some helpful hints
More informationImproving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationPATIENT INFORMATION. Patient s Name: Birthdate: ( ) F ( ) M LAST FIRST MI. ( ) Married ( ) Single ( ) Divorced ( ) Separated ( ) Widowed Occupation:
UPON COMPLETION OF PATIENT REGISTRATION PACKET, PLEASE BRING ALL FORMS TO YOUR APPOINTMENT. YOU MAY ALSO FAX COMPLETED FORMS TO THE OFFICE AT 910-575- 9103. THANK YOU. PATIENT INFORMATION Patient s Name:
More informationMedicine Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, June 2017
Medicine Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP to nurses, midwives, healthcare workers, agency staff, contract workers and volunteers by registered nurses and
More informationPatient Name Date of Birth / / We need the following information in order to comply with federal regulatory standards, thank you.
The Women s Clinic of Northern Colorado New Patient Exam Intake History (970) 493-7442 1107 S Lemay Ave, Ste 300, Fort Collins ~ 2500 Rocky Mountain Ave, North MOB, Ste 150, Loveland Patient Name Date
More informationSave up to $4,000 a year?!
Save up to $4,000 a year?! Indication and Usage HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is an immune globulin with a recombinant human hyaluronidase indicated
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2016
Patient Group Direction For The Administration Of Adrenaline (Epinephrine) By Trained Nurses In The Management Of Cardiac Arrest In The Medical High Dependency Unit/Coronary Care Unit (MHDU/CCU) Working
More informationPOLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case
POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case DOCUMENT NO: DN116 Lead author/initiator(s): Sarah Woodley Community Health Services Pharmacist sarah.woodley@ccs.nhs.uk
More informationNavigating Prior Authorizations and Appeals for DUPIXENT
Navigating Prior Authorizations and Appeals for DUPIXENT An informational guide with sample letters regarding coverage for DUPIXENT Please see throughout. Please click here for full Prescribing. Contents
More informationCyclophosphamide INFUSION Infusion 4 Plus
Cyclophosphamide Infusion Day DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Forename
More informationStatement of Financial Responsibility
Statement of Financial Responsibility Patient Name: Date: Acct : BIR JV, LLP including; Out-Patient, In-Patient and, Home Health Rehab appreciates the confidence you have shown in choosing us to provide
More informationThe Primary Care Trigger Tool: Practical Guidance
The Primary Care Trigger Tool: Practical Guidance Reviewing clinical records to detect and reduce patient safety incidents Index Content Page Introduction 2 What is a Trigger Tool Review? 2 What types
More informationWelcome to OPEN DOORS
Welcome to OPEN DOORS A support program for IPF patients taking OFEV (nintedanib) capsules For more information, call OPEN DOORS at 1-866-OPENDOOR (1-866-673-6366), or visit www.ofev.com IPF=idiopathic
More informationDr. Ian C. MacIntyre
coburg dentistryinc.bsc, DDS Patient Information Dr. Ian C. MacIntyre Name: DOB: (dd/mm/yyyy) / / Telephone: home cell work email: preferred contact method: Address: Street city province postal code Healthcard:
More informationPATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:
PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:
More informationLast Name First Middle. Mailing Address. City State Zip Phone. Date of Birth Age Soc. Sec# Cell. Employer Work Phone
Last Name First Middle Mailing Address City State Zip Phone Date of Birth Age Soc. Sec# Cell Employer Work Phone Email Address Emergency contact Phone # Relation: Name of Primary Insurance Policy # -----
More informationGETTING YOUR PATIENT STARTED WITH NORTHERA (droxidopa)
GETTING YOUR PATIENT STARTED WITH NORTHERA (droxidopa) NORTHERA is only available via Specialty Pharmacy and by using the enclosed NORTHERA Treatment and Prescription Forms. The NORTHERA Support Center
More informationPROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS
STANDARD OPERATING PROCEDURE PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS Issue History Issue Version one Purpose of Issue/Description of Change To facilitate patients
More informationNHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)
SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED
More informationAdministering Medicine Policy
Administering Medicine Policy Date Agreed: November 2015 Review Date: November 2016 Hove Junior School is committed to safeguarding and promoting the welfare of children and young people and expects all
More informationHome Intravenous Therapy HOPT (Home / Outpatient Parenteral Therapy)
Home Intravenous Therapy HOPT (Home / Outpatient Parenteral Therapy) Intermediate Care 0161 206 7017 All Rights Reserved 2017. Document for issue as handout. This booklet has been given to you because
More informationSection 7: Core clinical headings
Section 7: Core clinical headings Core clinical heading standards: the core clinical headings are those that are the priority for inclusion in EHRs, as they are generally items that are the priority for
More informationSocial care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1
Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPatient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.
Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. This document authorises the supply of Fusidic Acid Cream 2% by registered
More informationPatient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB
Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital
More informationADMINISTRATION OF INSULIN IN THE COMMUNITY BY SUPPORT WORKERS
Title Purpose ADMINISTRATION OF INSULIN IN THE COMMUNITY BY SUPPORT WORKERS This guideline is to assist: Service Providers (organisations and individuals), Participants, stakeholders and funders regarding
More informationFundamentals of Self-Limiting Conditions Prescribing for Manitoba Pharmacists. Ronald F. Guse Registrar College of Pharmacists of Manitoba (CPhM)
Fundamentals of Self-Limiting Conditions Prescribing for Manitoba Pharmacists Ronald F. Guse Registrar College of Pharmacists of Manitoba (CPhM) 1 Learning Objectives Upon successful completion of this
More informationMEDICINES RECONCILIATION GUIDELINE Document Reference
MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012
More informationFirst Aid and Medicine Policy
First Aid and Medicine Policy Policy area Students Staff Statutory regulation SLT Lead Robert Lobatto Version 2016.1 Approved 29 November 2016 Next review November 2019 First Aid and Medicine Policy 1.0
More informationDirectly Observed Therapy for Active TB Disease and Latent TB Infection
Directly Observed Therapy for Active TB Disease and Latent TB Infection Policy Number TB-5001 Effective Date (original issue) September 6, 1995 Revision Date (most recent) June 26, 2008 Subject Matter
More informationWorkers Compensation Demographic
Workers Compensation Demographic Account #: Physician: Last Name First Name MI: Address City State Zip Home Phone o OK to Leave Msg. Work Phone o OK to Leave Msg. Cell Phone o OK to Leave Msg. Email Do
More informationClinical Training: Medication Reconciliation. VNAA Best Practice for Home Health
Clinical Training: Medication Reconciliation VNAA Best Practice for Home Health Learning Objectives To understand why medication reconciliation is important to providing quality care To understand the
More informationPatient Name First Middle Last Address Street City State Zip Home Phone Work Phone Cell Phone. Date of Birth SS#
PATIENT WILL NOT BE SEEN WITHOUT PHOTO ID Patient Information Kimberly Walpert, M.D. 1199 Prince Avenue Athens GA 30606 Ph 706-475-1870 Fax 706-475-1879 www.athensbrainandspine.com Patient Name First Middle
More informationPATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationMedical Department Employee Return to Work Information Sheet
Medical Department Employee Return to Work Information Sheet The Norfolk Southern Medical Department s (NSMD) process for returning you to work following a long non-medical absence or a medically-related
More informationAdverse Drug Events: A Focus on Anticoagulation Steve Meisel, Pharm.D., CPPS Director of Patient Safety Fairview Health Services, Minneapolis, MN
Adverse Drug Events: A Focus on Anticoagulation Steve Meisel, Pharm.D., CPPS Director of Patient Safety Fairview Health Services, Minneapolis, MN Fairview Health Services 6 hospitals, ranging from rural
More informationGMS Contract in Wales Enhanced Service for Care Homes Specification
GMS Contract in Wales 2008-09 Enhanced Service for Care Homes Specification Doc 5 1. Introduction Many older people enter care homes to receive supportive care and these populations have increasing dependency
More informationManaging medicines in care homes
Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience
More informationClinical Guideline for Clinical Imaging Referral Protocol for Upper & Lower GI Non medical Endoscopist within RCHT. 1. Aim/Purpose of this Guideline
Clinical Guideline for Clinical Imaging Referral Protocol for Upper & Lower GI Non medical Endoscopist. 1. Aim/Purpose of this Guideline 1.1 This protocol applies to upper & lower GI Non medical Endoscopist
More informationPATIENT INFORMATION. Address: Sex: City: State: address: Cell Phone: Home Phone: Work Phone: address: Cell Phone:
PATIENT INFORMATION Name: _ DOB: _ Age: Address: _Sex: City: _ State: _ Zip: _ Email address: Cell Phone: _ Home Phone: Work Phone: _ Responsible Party (if different from above) Name: DOB: Address: E-mail:
More informationMedication Management Policy and Procedures
POLICY STATEMENT This policy establishes guidelines for ensuring safe and correct management of client medications in accordance with legislative and regulatory requirements and professional practice competency
More informationNational Care of the Dying Audit Hospitals (NCDAH) Round 3
National Care of the Dying Audit Hospitals (NCDAH) Round 3 This audit is being led by the Marie Curie Palliative Care Institute Liverpool in collaboration with the Royal College of Physicians, and is supported
More information